Scientists continue to explore tissue biology and cellular signaling regarding this peptide
This message will disappear when all data is loaded
Clinical Studies 14.1 Glycemic Control in Adults with Type 2 Diabetes Mellitus Overview of Clinical Trials of FARXIGA in Adults with Type 2 Diabetes Mellitus FARXIGA has been studied in adult patients as monotherapy, in combination with metformin, pioglitazone, sulfonylurea (glimepiride), sitagliptin (with or without metformin), metformin plus a sulfonylurea, or insulin (with or without other oral antidiabetic therapy), compared to a sulfonylurea (glipizide), and in combination with a GLP-1 receptor agonist (exenatide extended release) added on to metformin
88 A study in children with trichotillomania by the same team, however, found no benefits of NAC at a dose titrated from 600 mg per day to 2400 mg per day, study duration 12 weeks
Statistically significantly greater proportions of patients treated with SAXENDA achieved 5% and 10% weight loss than those treated with placebo
